SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Express Scripts Holding Company to Cigna Corporation is Fair to Shareholders – ESRX

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Express Scripts Holding Company ("Express Scripts" or the "Company") ESRX stock prior to March 8, 2018.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Express Scripts to Cigna Corporation CI. Under the terms of the transaction, Express Scripts shareholders will receive $48.75 in cash and 0.2434 shares of the combined company's stock for each share of Express Scripts stock they own. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/express-scripts

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Express Scripts breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Cigna Corporation is underpaying for Express Scripts shares, thus unlawfully harming Express Scripts shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!